CAS: 126094-21-1; (2R,3S,4R,5R)-2,3,4,5,6-Pentahydroxy-N-(3-Methoxypropyl)Hexanamide

专利信息

专利号:CA-2640585-A1
优先权日:2003-02-05
标题 :Synthesis of 2-butyl-3-(2'-(1-trityl-1h-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspirol{4,4}-non-ene-4-one

专利号:US-2009304615-A1
优先权日:2007-11-14
标 题 :Tricyclic compounds as melanogenesis modifiers and uses thereof
发明人：ORLOW SETH J; KOMATSU LI NI
权利人:ORLOW SETH J; KOMATSU LI NI
摘要:A method of identification of tricyclic compounds (formula I) that control melanin synthesis (melanogenesis), and the use of such compounds and compositions thereof to modify (e.g., inhibit) melanin production are disclosed. n n n n n n n n n n The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to aberrant melanogenesis activity including by way of non-limiting example, hyperpigmentation and others.

专利号:US-2009298868-A1
优先权日:2007-11-14
标 题:Quinoline compounds as melanogenesis modifiers and uses thereof
发明人：ORLOW SETH J; KOMATSU LI NI
权利人:ORLOW SETH J; KOMATSU LI NI
摘要:A method of identification of quinoline compounds (formula I) that modify melanin synthesis (melanogenesis), and the use of such compounds and compositions thereof to control (e.g., inhibit) melanin production are disclosed. n n n n n n n n n n The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to aberrant melanogenesis activity including by way of non-limiting example, pigmentation deficiencies (albinism) and hyperpigmentation and others.

专利号:US-2010093823-A1
优先权日:2008-04-30
标 题 :Steroidal compounds as melanogenesis modifiers and uses thereof
发明人：ORLOW SETH J; KOMATSU LI NI
权利人:ORLOW SETH J; KOMATSU LI NI
摘要:A method for the identification of compounds) that control melanin synthesis (melanogenesis), and the preparation and use of such compounds, and compositions and formulations thereof to modify (e.g., inhibit) melanin production are disclosed. A representative compound of the invention is defined by formula I: n n n n n n n n n n The compounds may be prepared as pharmaceutical and cosmetic compositions, and in one embodiment, may be prepared in combination with each other, and with other melanogenesis inhibiting formulations. The compounds, compositions and formulations of the invention may be used for the prevention and treatment of conditions that are causally related to aberrant melanogenesis activity including, by way of non-limiting example, hyperpigmentation and others.